A First in human study of 18-F PI-2620 evaluating tau in AD and other tauopathies

Trial Profile

A First in human study of 18-F PI-2620 evaluating tau in AD and other tauopathies

Recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Feb 2018

At a glance

  • Drugs PI 2620 (Primary)
  • Indications Alzheimer's disease; Progressive supranuclear palsy
  • Focus Diagnostic use; First in man
  • Most Recent Events

    • 06 Feb 2018 According to an AC Immune media release, data from the study will be present at the AAT-AD/PDTM conference 2018.
    • 20 Jul 2017 Results presented at the Alzheimer's Association International Conference 2017
    • 03 Apr 2017 First results from this trial were presented at the International conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders (AD/PD), according to a Piramal Imaging media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top